Navigation Links
Higher co-payments increase chance of early discontinuation, inadequate use of breast cancer therapy
Date:12/11/2010

SAN ANTONIO A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early-stage breast cancer.

Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, presented detailed study results at the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.

Previous research has identified several factors affecting patient compliance with use of adjuvant aromatase inhibitors, such as young and old age, severity of side effects and belief that the medication is useful.

Hershman and colleagues examined the impact of prescription co-payments on hormone therapy use. Working with the Medco Research Institute, a wholly owned subsidiary of Medco Health Solutions, Inc., anonymous patient information was used to target women older than 50 years who were prescribed aromatase inhibitors for early breast cancer.

"We looked at two different factors: women who discontinued use altogether or had no subsequent refills and those that did not refill their prescription on time or did not take the medication at least 80 percent of the time," said Hershman.

Results showed that of the 8,110 women aged 50 to 65 years, 21.1 percent stopped taking the medication and of those who properly continued with their regimen 10.3 percent did not take the medication as directed over the two-year period. Of the 14,050 women 65 years or older, almost 25 percent stopped taking the medication and of those who continued, 8.9 percent were non-adherent.

Co-payments were categorized as less than $30, between $30 and $89.99, and $90 or more. The 90-day co-payments ranged from $0 to $893.49.

In the 65 and older group, women were more likely to discontinue medication use if they fell in the co-payment categories above $30. However, it was not until the co-payment reached $90 or more that the less than 65 age group was more likely to discontinue use or not take it as prescribed.

Additionally, the study results showed that women whose prescriptions came from a primary care doctor or women who were prescribed many other medications were also more likely to stop taking the medications or not take them as prescribed.

"When we have highly effective medications available, we need to try to set limits on potential barriers to use like co-payments," said Hershman. Based on these findings, "future public policy efforts should be directed towards reducing financial constraints as a means of increasing the complete use of these medications."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Snakes, salamanders and other creatures thrive in areas with higher deer populations
2. Children distressed by family fighting have higher stress hormones
3. Researchers push nature beyond its limits to create higher-density biofuels
4. Teenage boys who eat fish at least once a week achieve higher intelligence scores
5. Genetic irregularities linked to higher risk of COPD among smokers
6. Business, scientific, higher education groups laud President Obamas commitment to science
7. Immigrant women may be at higher risk of having a baby with a birth defect
8. People of higher socioeconomic status choose better diets -- but pay more per calorie
9. Bioethanols impact on water supply 3 times higher than once thought
10. Metabolic syndrome risk factors drive significantly higher health care costs
11. Ethiopias climate 27 million years ago had higher rainfall, warmer soil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
Breaking Biology News(10 mins):
(Date:8/17/2017)... ... 17, 2017 , ... CNA Finance Chief Research Analyst, Kenny ... update on Aytu Bioscience and cited promising increases in the prescription rates for ... for Natesto® have more than doubled since March of this year and on ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... research and personalized medicine, today announced the launch of a new breast cancer ... The study’s goal is to evaluate the potential for early detection of recurrent ...
(Date:8/16/2017)... ... , ... Tunnell Consulting announced today that four of the firm’s ... and Expo , to be held October 29 through November 1 in San Diego ... advance patient therapies.” , The ISPE Annual Meeting and Expo will feature several interactive ...
(Date:8/16/2017)... Arizona (PRWEB) , ... August ... ... proud to introduce the Fluidnatek® Electrospinning and Electrospraying ... electrospraying equipment scales from table-top equipment for the lab to fully automated ...
Breaking Biology Technology: